Composite The Duke University Medical Center (DUMC) Clinical Trials Unit (CTU) proposes to address the key scientific areas of translational research and optimization of clinical management in children and adults, and prevention of mother to child transmission.The CTU and its affiliated Clinical Research Sites (CRS's) bring scientific leadership, a rich history of successful collaborative clinical research within networks, a strong and efficient organizational foundation for the conduct of rigorous clinical research, and access to growing numbers of underserved persons living with HIV/AIDS (PLWHA) in the US Southeast and Tanzania. The scientific leadership of the CTU and CRS investigators is reflected in their past participation in the Adult and Pediatric AIDS Clinical Trials Groups (ACTG's), and the expanding portfolio of NIH-funded research at DUMC and the Kilimanjaro Christian Medical Centre (KCMC). The three CRS's included in the CTU proposal each bring unique value and are highly motivated to perform the proposed work, and together they will constitute a formidable research enterprise. Their interactions will be guided by an administrative structure which supports a dynamic intellectual environment to enhance scientific creativity, clear roles and responsibilities for investigators and staff, facile and regular communications, harmonized standard operating procedures across CRS's which emphasize CTU accountability through quality management, and a strong commitment to serve the community of PLWHA. The clarity of CTU and CRS organization and operations will ensure that it operates efficiently to perform clinical research at the highest standard, with the ability to rapidly respond to evolving opportunities.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
3UM1AI069484-07S1
Application #
8788082
Study Section
Special Emphasis Panel (ZAI1-SR-A (M2))
Program Officer
Pouliot, Eileen M
Project Start
2007-02-01
Project End
2014-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
7
Fiscal Year
2014
Total Cost
$481,517
Indirect Cost
$54,712
Name
Duke University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Moore, Carrie B; Verma, Anurag; Pendergrass, Sarah et al. (2015) Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. Open Forum Infect Dis 2:ofu113
Brown, Todd T; Moser, Carlee; Currier, Judith S et al. (2015) Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. J Infect Dis 212:1241-9
Wanga, Valentine; Venuto, Charles; Morse, Gene D et al. (2015) Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 25:450-61
Lehmann, David S; Ribaudo, Heather J; Daar, Eric S et al. (2015) Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Pharmacogenet Genomics 25:51-9
Vardhanabhuti, Saran; Ribaudo, Heather J; Landovitz, Raphael J et al. (2015) Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. Open Forum Infect Dis 2:ofv085
Cillo, Anthony R; Hilldorfer, Benedict B; Lalama, Christina M et al. (2015) Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. AIDS 29:2121-9
Thio, Chloe L; Smeaton, Laura; Hollabaugh, Kimberly et al. (2015) Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks. AIDS 29:1173-82
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60

Showing the most recent 10 out of 50 publications